Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.22.0.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:        
Research and development $ 9,452 $ 4,496 $ 15,226 $ 6,840
General and administrative 2,697 2,656 4,563 3,935
Total operating expenses 12,149 7,152 19,789 10,775
Operating loss (12,149) (7,152) (19,789) (10,775)
Non-operating income (expense):        
Interest expense (445)   (888)  
Gain (loss) on change in fair value of embedded derivative liability (12)   4  
Employee retention credit     231  
Other income 13 55 13 58
Total non-operating income (expense), net (444) 55 (640) 58
Net loss $ (12,593) $ (7,097) $ (20,429) $ (10,717)
Net loss per common share - basic (in dollars per share) $ (0.80) $ (0.88) $ (1.69) $ (1.54)
Net loss per common share - diluted (in dollars per share) $ (0.80) $ (0.88) $ (1.69) $ (1.54)
Weighted average number of common shares outstanding - basic (in shares) 15,680 8,045 12,097 6,956
Weighted average number of common shares outstanding - diluted (in shares) 15,680 8,045 12,097 6,956